Komlossy Law, P.A. is investigating the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ: HPTX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to complete a sale of the Company to Horizon Pharma plc (“Horizon”). Pursuant to the terms of the proposed transaction, Hyperion shareholders are to receive $46.00 for each share of the Company. This represents only a 7.6% premium based on Hyperion’s March 27, 2015 closing price. The proposed consideration also falls well below recent price targets set by industry analysts.
The investigation involves whether the Board of Directors of Hyperion breached its fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether the transaction is fair to shareholders with respect to price, process and disclosure of all material information.
If you own Hyperion stock and wish to obtain additional information about your rights as a shareholder at no charge, or if you have information about the above investigation, please contact Emily C. Komlossy or Ross Appel via email at eck@komlossylaw.com or raa@komlossylaw.com, respectively, or by telephone toll free at (855) 858-1233.